These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 39067959)

  • 21. Characteristics and treatment outcomes of patients with MDR and XDR tuberculosis in a TB referral hospital in Beijing: a 13-year experience.
    Liu CH; Li L; Chen Z; Wang Q; Hu YL; Zhu B; Woo PC
    PLoS One; 2011 Apr; 6(4):e19399. PubMed ID: 21559362
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment efficacy of drug-resistant tuberculosis in Bashkortostan, Russia: A retrospective cohort study.
    Yunusbaeva M; Borodina L; Alekseev P; Davydov R; Yunusbaev U; Sharipov R; Bilalov F; Yunusbayev B
    Int J Infect Dis; 2019 Apr; 81():203-209. PubMed ID: 30794942
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Isoniazid mono-resistant tuberculosis: Time to take it seriously.
    Garg K; Saini V; Dhillon R; Agarwal P
    Indian J Tuberc; 2019 Apr; 66(2):247-252. PubMed ID: 31151492
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of Highly Drug-Resistant Pulmonary Tuberculosis.
    Conradie F; Diacon AH; Ngubane N; Howell P; Everitt D; Crook AM; Mendel CM; Egizi E; Moreira J; Timm J; McHugh TD; Wills GH; Bateson A; Hunt R; Van Niekerk C; Li M; Olugbosi M; Spigelman M;
    N Engl J Med; 2020 Mar; 382(10):893-902. PubMed ID: 32130813
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intermittent treatment interruption and its effect on multidrug resistant tuberculosis treatment outcome in Ethiopia.
    Tola HH; Holakouie-Naieni K; Mansournia MA; Yaseri M; Tesfaye E; Mahamed Z; Sisay MM
    Sci Rep; 2019 Dec; 9(1):20030. PubMed ID: 31882784
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictors of recurrence of multidrug-resistant and extensively drug-resistant tuberculosis.
    Blöndal K; Viiklepp P; Guðmundsson LJ; Altraja A
    Int J Tuberc Lung Dis; 2012 Sep; 16(9):1228-33. PubMed ID: 22748131
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predictors of poor treatment outcome in multi- and extensively drug-resistant pulmonary TB.
    Kliiman K; Altraja A
    Eur Respir J; 2009 May; 33(5):1085-94. PubMed ID: 19164345
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diabetes is Associated with Severe Adverse Events in Multidrug-Resistant Tuberculosis.
    Muñoz-Torrico M; Caminero-Luna J; Migliori GB; D'Ambrosio L; Carrillo-Alduenda JL; Villareal-Velarde H; Torres-Cruz A; Flores-Vergara H; Martínez-Mendoza D; García-Sancho C; Centis R; Salazar-Lezama MÁ; Pérez-Padilla R
    Arch Bronconeumol; 2017 May; 53(5):245-250. PubMed ID: 28089216
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Linezolid: an effective, safe and cheap drug for patients failing multidrug-resistant tuberculosis treatment in India.
    Singla R; Caminero JA; Jaiswal A; Singla N; Gupta S; Bali RK; Behera D
    Eur Respir J; 2012 Apr; 39(4):956-62. PubMed ID: 21965225
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rapid impact of effective treatment on transmission of multidrug-resistant tuberculosis.
    Dharmadhikari AS; Mphahlele M; Venter K; Stoltz A; Mathebula R; Masotla T; van der Walt M; Pagano M; Jensen P; Nardell E
    Int J Tuberc Lung Dis; 2014 Sep; 18(9):1019-25. PubMed ID: 25189547
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Different macrophage polarization between drug-susceptible and multidrug-resistant pulmonary tuberculosis.
    Cho HJ; Lim YJ; Kim J; Koh WJ; Song CH; Kang MW
    BMC Infect Dis; 2020 Jan; 20(1):81. PubMed ID: 31996142
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment outcome of patients having extensively drug-resistant tuberculosis in Gujarat, India.
    Prajapati K; Mishra V; Desai M; Solanki R; Naik P
    Int J Mycobacteriol; 2017; 6(3):289-295. PubMed ID: 28776529
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Unacceptable treatment outcomes and associated factors among India's initial cohorts of multidrug-resistant tuberculosis (MDR-TB) patients under the revised national TB control programme (2007-2011): Evidence leading to policy enhancement.
    Parmar MM; Sachdeva KS; Dewan PK; Rade K; Nair SA; Pant R; Khaparde SD
    PLoS One; 2018; 13(4):e0193903. PubMed ID: 29641576
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
    Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ
    Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High degree of fluoroquinolone resistance among pulmonary tuberculosis patients in New Delhi, India.
    Sharma R; Sharma SK; Singh BK; Mittal A; Kumar P
    Indian J Med Res; 2019 Jan; 149(1):62-66. PubMed ID: 31115377
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A study of clinical profile of cases of MDR-TB and evaluation of challenges faced in initiation of second line Anti tuberculosis treatment for MDR-TB cases admitted in drug resistance tuberculosis center.
    Mukati S; Julka A; Varudkar HG; Singapurwala M; Agrawat JC; Bhandari D; Jain A
    Indian J Tuberc; 2019 Jul; 66(3):358-363. PubMed ID: 31439180
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Determinants of multidrug-resistant tuberculosis in patients who underwent first-line treatment in Addis Ababa: a case control study.
    Hirpa S; Medhin G; Girma B; Melese M; Mekonen A; Suarez P; Ameni G
    BMC Public Health; 2013 Aug; 13():782. PubMed ID: 23981845
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug resistance characteristics and cluster analysis of M. tuberculosis in Chinese patients with multiple episodes of anti-tuberculosis treatment.
    Hu Y; Zhao Q; Werngren J; Hoffner S; Diwan VK; Xu B
    BMC Infect Dis; 2016 Jan; 16():4. PubMed ID: 26739444
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alarming levels of drug-resistant tuberculosis in HIV-infected patients in metropolitan Mumbai, India.
    Isaakidis P; Das M; Kumar AM; Peskett C; Khetarpal M; Bamne A; Adsul B; Manglani M; Sachdeva KS; Parmar M; Kanchar A; Rewari BB; Deshpande A; Rodrigues C; Shetty A; Rebello L; Saranchuk P
    PLoS One; 2014; 9(10):e110461. PubMed ID: 25333696
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis.
    Pym AS; Diacon AH; Tang SJ; Conradie F; Danilovits M; Chuchottaworn C; Vasilyeva I; Andries K; Bakare N; De Marez T; Haxaire-Theeuwes M; Lounis N; Meyvisch P; Van Baelen B; van Heeswijk RP; Dannemann B;
    Eur Respir J; 2016 Feb; 47(2):564-74. PubMed ID: 26647431
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.